Education

Personal Finance How To Use TipRanks TipRanks Labs Webinar Center Glossary FAQs

About Us

About TipRanks Contact Us Careers Reviews Mobile APP

Working with TipRanks

Enterprise Solutions Advertise with Us Top Online Brokers Become an Affiliate

News Trending Portfolio

TOOLS

Top Smart Score Stocks

STOCKS

Best High Yield Dividend Stocks

Dividend Aristocrats

Dividend Stock Comparison

New

Dividend Calculator

Dividend Returns Comparison

Dividend Calendar

Top Analysts

Top Financial Bloggers

Top-Performing Corporate Insiders

Top Hedge Fund Managers

Top Research Firms

Top Individual Investors

News

Portfolio

Personal Finance Center

Mortgages

Loans

Investing & Retirement

Spending & Savings

Calculators

Compound Interest Calculator

Student Loan Calculator

401k Retirement Calculator

Education

About Us

Working with TipRanks

Enterprise Solutions

Top Online Brokers

Become an Affiliate

Takeda Pharmaceutical Co Ltd (JP:4502)

TSE/TYO:4502

4502

Takeda Pharmaceutical Co

RESEARCH TOOLS

Top Smart Score Stocks

Stock Screener

reports

Holding JP:4502?

Track your performance easily

Link Broker

Takeda Pharmaceutical Co (4502) Stock Price & Analysis

3 Followers

4502 Stock Chart & Stats

Advanced Chart >

Day’s Range¥0 - ¥0

52-Week Range¥3,852.00 - ¥4,494.00

Previous Close¥4,154

Volume9.61M

Average Volume (3M)3.86M

Market Cap

¥6.58T

Enterprise ValueN/A

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)22.5

Beta0.52

Next Earnings

Jan 30, 2025

EPS Estimate

¥32.82

Next Dividend Ex-Date

Mar 28, 2025

Dividend Yield5.11%

Share Statistics

EPS (TTM)184.31

Shares OutstandingN/A

10 Day Avg. VolumeN/A

30 Day Avg. Volume3,861,240

Standard DeviationN/A

R-SquaredN/A

AlphaN/A

Financial Highlights & Ratios

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

Price to Cash Flow (P/CF)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

¥4,500.44

Price Target Upside8.34% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering3

Takeda Pharmaceutical Co News

PremiumThe Fly

Hutchmed to receive milestone payment following Takeda launch of Fruzaqla

4d ago

HCM

TAK

PremiumThe Fly

Biotech Alert: Searches spiking for these stocks today

19d ago

RDY

TAK

PremiumThe Fly

Stifel bullish on orexin, upgrades Alkermes to Buy

22d ago

TAK

ALKS

PremiumThe Fly

Hutchmed to receive $20M milestone payment from Takeda for Fruzaqla sales

27d ago

HCM

TAK

PremiumCompany Announcements

Takeda Pharmaceutical Reports Strong Revenue Growth in 2024

26d ago

PremiumCompany Announcements

Takeda Reports Impressive Profit Growth Amid Revenue Rise

27d ago

PremiumCompany Announcements

Takeda Pharmaceutical Raises FY2024 Financial Forecast

27d ago

PremiumThe Fly

Spyre Therapeutics price target raised to $65 from $50 at Guggenheim

1M ago

TAK

SYRE

See More TKPHF News >

Options Prices

Currently, No data available

---

Ownership Overview

― Insiders

7.41% Mutual Funds

<0.01% Other Institutional Investors

83.69% Public Companies and

Individual Investors

Detailed Ownership Overview >

4502 FAQ

What was Takeda Pharmaceutical Co Ltd’s price range in the past 12 months?

Takeda Pharmaceutical Co Ltd lowest stock price was ¥3852.00 and its highest was ¥4494.00 in the past 12 months.

What is Takeda Pharmaceutical Co Ltd’s market cap?

Currently, no data Available

When is Takeda Pharmaceutical Co Ltd’s upcoming earnings report date?

Takeda Pharmaceutical Co Ltd’s upcoming earnings report date is Jan 30, 2025 which is in 65 days.

How were Takeda Pharmaceutical Co Ltd’s earnings last quarter?

Takeda Pharmaceutical Co Ltd released its earnings results on Oct 31, 2024. The company reported ¥58.21 earnings per share for the quarter, beating the consensus estimate of ¥37.045 by ¥21.165.

Is Takeda Pharmaceutical Co Ltd overvalued?

According to Wall Street analysts Takeda Pharmaceutical Co Ltd’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Takeda Pharmaceutical Co Ltd pay dividends?

Takeda Pharmaceutical Co Ltd pays a Annually dividend of ¥98 which represents an annual dividend yield of 5.11%. See more information on Takeda Pharmaceutical Co Ltd dividends here

What is Takeda Pharmaceutical Co Ltd’s EPS estimate?

Takeda Pharmaceutical Co Ltd’s EPS estimate is ¥32.82.

How many shares outstanding does Takeda Pharmaceutical Co Ltd have?

Takeda Pharmaceutical Co Ltd has 1,590,937,600 shares outstanding.

What happened to Takeda Pharmaceutical Co Ltd’s price movement after its last earnings report?

Takeda Pharmaceutical Co Ltd reported an EPS of ¥58.21 in its last earnings report, beating expectations of ¥37.045. Following the earnings report the stock price went up 0.306%.

Which hedge fund is a major shareholder of Takeda Pharmaceutical Co Ltd?

Currently, no hedge funds are holding shares in JP:4502

---

Takeda Pharmaceutical Co Stock Smart Score

Unlock Smart Score

Analyst Consensus

Moderate Buy

Average Price Target:
¥4,500.44 (8.34% Upside)

Technicals

Fundamentals

Return on Equity

4.02%

Trailing 12-Months

Asset Growth

2.23%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Takeda Pharmaceutical Co Ltd

Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.

---

4502 Company Deck

---

4502 Earnings Call

Q2 2024

0:00 / 0:00

---

4502 Stock 12 Month Forecast

Average Price Target

¥4,500.44

▲(8.34% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3874":"¥3,874","4337":"¥4,337","4800":"¥4,800","4105.5":"¥4,105.5","4568.5":"¥4,568.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":4799.998530432,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">¥4.80K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4500.44312,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">¥4.50K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4199.998714128,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">¥4.20K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3874,4105.5,4337,4568.5,4800],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2024","6":"Jun<br/>2024","9":"Aug<br/>2024","12":"Nov<br/>2024","25":"Nov<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4270,4310.769117725538,4351.538235451077,4392.307353176615,4433.076470902154,4473.845588627692,4514.614706353231,4555.383824078769,4596.152941804307,4636.922059529846,4677.691177255385,4718.460294980923,4759.2294127064615,{"y":4799.998530432,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4270,4287.726393846154,4305.4527876923075,4323.179181538461,4340.905575384615,4358.631969230769,4376.358363076923,4394.084756923077,4411.811150769231,4429.537544615385,4447.263938461539,4464.990332307692,4482.716726153846,{"y":4500.44312,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4270,4264.615285702153,4259.230571404308,4253.845857106461,4248.4611428086155,4243.076428510769,4237.691714212923,4232.306999915077,4226.922285617231,4221.537571319384,4216.152857021539,4210.768142723692,4205.383428425846,{"y":4199.998714128,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3987.419,"date":1701388800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":3875.569,"date":1704067200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":4116.477,"date":1706745600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":4195.824,"date":1709251200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":4062.985,"date":1711929600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":4047.354,"date":1714521600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":4076.662,"date":1717200000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":4134.3,"date":1717718400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4145.046,"date":1720137600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4091.315,"date":1722556800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4172.399,"date":1725580800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4240,"date":1728000000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4270,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >

Technical Analysis

Similar Stocks

Takeda Pharmaceutical Co

―

SNY

Sanofi

―

NVS

Novartis

―

BAYRY

Bayer

―

AZN

AstraZeneca

―

Compare JP:4502 Stocks >

Best Analysts Covering 4502

1 Year

Tony RenMacquarie

1 Year Success Rate

0/2 ratings generated profit

1 Year Average Return

-8.45%

reiterated a buy rating last month

Copying Tony Ren's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -8.45% per trade.

Best Analyst Covering >

Popular Stocks

---

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing